Skip to content
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
Profitability
Gross margin52.1%+0.4pp51.6%+0.9pp50.7%+1.5pp49.2%+2.5pp46.7%+2.1pp
Operating margin-33.9%+0.5pp-34.4%+1.8pp-36.2%+3.1pp-39.3%+18.6pp-57.9%+5.3pp
Net margin-19.8%-0.3pp-19.6%+1.1pp-20.6%+2.9pp-23.5%+31.5pp-55%+4.8pp
EBITDA margin-27.9%+0.2pp-28.1%+1.5pp-29.6%+2.7pp-32.3%+17.6pp-49.9%+4.3pp
Free cash flow margin-23.2%-1.1pp-22.1%-2.1pp-20.1%-1.1pp-19%-0.1pp-18.8%+1.9pp
Returns
Return on equity-18.2%-1.4pp-16.8%-0.4pp-16.4%+1.1pp-17.6%+20.6pp-38.2%-0.5pp
Return on assets-12.8%-0.5pp-12.3%+0.1pp-12.4%+0.9pp-13.3%+16.1pp-29.4%0.0pp
Return on invested capital-36.4%-0.4pp-36%+2.6pp-38.6%+1.9pp-40.5%+15.0pp-55.4%+0.7pp
Efficiency
Asset turnover0.6×0.0×0.6×0.0×0.6×0.0×0.6×0.0×0.5×0.0×
Inventory turnover7.2×+0.5×6.7×-0.4×7.1×+0.3×6.8×-0.5×7.2×+0.5×
Liquidity
Current ratio2.7×-1.1×3.8×+0.1×3.6×-0.3×3.9×-0.6×4.5×-0.4×
Quick ratio2.4×-1.0×3.4×0.0×3.3×-0.3×3.6×-0.6×4.2×-0.4×
Cash ratio-0.8×1.9×-0.2×-0.3×2.3×-0.5×2.8×-0.4×
Leverage
Debt-to-equity0.2×0.0×0.2×+0.1×0.2×0.0×0.2×0.0×0.2×0.0×
Debt-to-assets0.2×0.0×0.2×0.0×0.1×0.0×0.1×0.0×0.2×0.0×
Per Share
Book value per share$7.38-1.2%$7.47-5.6%$7.91+1.1%$7.82+6.0%$7.38-4.3%
Valuation
Market capitalization$2.91B+50.2%$1.94B+14.2%$1.7B-20.9%$2.15B-8.3%$2.34B-15.1%
Enterprise value$2.9B+52.5%$1.9B+18.6%$1.6B-21.3%$2.04B-8.4%$2.22B-15.5%
Price / sales7.1×+2.2×+0.4×4.5×-1.4×5.9×-0.8×6.7×-1.6×
Price / book6.4×+2.1×4.3×+0.7×3.6×-0.9×4.5×-0.8×5.3×-0.7×
EV / sales7.1×+2.2×4.9×+0.6×4.3×-1.4×5.6×-0.8×6.4×-1.6×
Free cash flow yield-3.3%+1.2pp-4.5%0.0pp-4.5%-1.3pp-3.2%-0.4pp-2.8%-0.3pp
Earnings yield-2.8%+1.2pp-3.9%+0.6pp-4.6%-0.6pp-4%+4.2pp-8.2%-1.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Twist Bioscience Corporation's profit margins?
Twist Bioscience Corporation (TWST) runs a 52.1% gross margin and a -33.9% operating margin, with a -19.8% net margin.
Where do Twist Bioscience Corporation's ratios come from?
Every ratio is computed from Twist Bioscience Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.